HRMY vs. TARO, XNCR, AIMT, RARX, OPK, JAZZ, BPMC, OGN, IONS, and BBIO
Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Aimmune Therapeutics (AIMT), Ra Pharmaceuticals (RARX), OPKO Health (OPK), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.
Harmony Biosciences (NASDAQ:HRMY) and Taro Pharmaceutical Industries (NYSE:TARO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Harmony Biosciences has higher earnings, but lower revenue than Taro Pharmaceutical Industries. Harmony Biosciences is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Harmony Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 91.4% of Taro Pharmaceutical Industries shares are owned by institutional investors. 30.8% of Harmony Biosciences shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Harmony Biosciences had 1 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 4 mentions for Harmony Biosciences and 3 mentions for Taro Pharmaceutical Industries. Harmony Biosciences' average media sentiment score of 0.70 beat Taro Pharmaceutical Industries' score of -0.10 indicating that Harmony Biosciences is being referred to more favorably in the media.
Harmony Biosciences has a net margin of 22.30% compared to Taro Pharmaceutical Industries' net margin of 8.56%. Harmony Biosciences' return on equity of 28.26% beat Taro Pharmaceutical Industries' return on equity.
Harmony Biosciences presently has a consensus target price of $40.63, indicating a potential upside of 38.18%. Taro Pharmaceutical Industries has a consensus target price of $43.00, indicating a potential upside of 0.42%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Harmony Biosciences is more favorable than Taro Pharmaceutical Industries.
Taro Pharmaceutical Industries received 250 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 62.05% of users gave Taro Pharmaceutical Industries an outperform vote while only 60.29% of users gave Harmony Biosciences an outperform vote.
Summary
Harmony Biosciences beats Taro Pharmaceutical Industries on 13 of the 18 factors compared between the two stocks.
Get Harmony Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harmony Biosciences Competitors List
Related Companies and Tools
